Proteon Therapeutics kidney drug fails key study, shares slump

(Reuters) - Proteon Therapeutics Inc said on Tuesday that its experimental chronic kidney disease drug failed to meet the main goal in a late-stage study, sending its shares plunging 70 percent in premarket trading.